Genomic Alterations in Lung and Thyroid Cancer: Guidance on Molecular Testing for Precision Therapy

Join us for this live CME/CPE/CE/ABIM MOC and ABPath–certified workshop series reviewing the best practices and latest advances in the management of lung or thyroid cancers with NTRK or RET gene fusions. Register today!

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Agenda

Welcome, Introduction, Polling Questions

Overview and Rationale for Testing for NTRK Gene Fusions

  • TRK biology and oncogenesis/NTRK fusion frequency and diagnosis across histologies
  • Clinical data and current indications for TRK inhibitors
  • Future directions

Overview and Rationale for Testing RET Gene Fusions

  • RET alterations and oncogenesis/RET fusion frequency and diagnosis across histologies
  • Clinical data and current indications for RET inhibitors
  • Future directions

Evidence Based Testing Strategies to Detect Appropriate Fusions and Mutations

  • Methods of detection of NTRK and RET fusions

Audience Question and Answer Session

Events

Date / Time
Event Details

Faculty

Co-Chair
Saad A. Khan, MD

Assistant Professor of Medicine (Oncology)
Leader
, Endocrine Cancers Research Group
Stanford Cancer Institute
Stanford University
Stanford, California

Co-Chair
Sandip P. Patel, MD

Professor
Division of Hematology and Medical Oncology
UC San Diego Moores Cancer Center
La Jolla, California

Faculty
Jessica Bauman, MD

Associate Professor
Department of Hematology-Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Faculty
Jonathan Dowell, MD

Associate Professor of Internal Medicine 
Department of Hematology/Oncology
University of Texas Southwestern Medical Center
Chief, Section of Hematology/Oncology
Dallas VA Medical Center
Dallas, Texas

Faculty
Nagla Karim, MD

Faculty
Sylvia Lee, MD

Faculty
Nisha Mohindra, MD

Associate Professor
Department of Medicine
Northwestern University
Chicago, Illinois

Faculty
Conor Ernst Steuer, MD

Associate Professor
Department of Medical Oncology
Winship Cancer Institute of Emory University
Atlanta, Georgia

Goal Statement
The goal of this activity is to improve the knowledge, competence, and performance of learners to assess new and emerging biomarkers and planning individualized treatment for patient with lung or thyroid cancers.

Target Audience
This program is intended for medical oncologists, pathologists, endocrinologists, surgeons, interventional radiologists, nurses, pharmacists, and other healthcare professionals who care for patients with lung or thyroid cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Order appropriate assays or molecular tests to detect oncogenic gene fusions in patients with NSCLC and thyroid cancer
  • Appraise emerging clinical data supporting the use of TRK inhibition in NTRK fusion–positive NSCLC and thyroid cancer and RET inhibition in RET-altered lung and thyroid cancer
  • Formulate strategies for integrating TRK and RET inhibitors into the management of eligible patients with NSCLC and thyroid cancer, based on expert recommendations and oncogenic gene fusion status
  • Develop treatment strategies for patients with cancer who develop acquired resistance to first-generation TRK and RET inhibitor therapy
  • Manage treatment-related symptoms associated with the treatment of RET altered or NTRK fusion–positive cancer
  • Refer eligible patients with NTRK fusion–positive and RET-altered NSCLC and thyroid cancer for ongoing clinical trials

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-214-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

American Board of Pathology Continuing Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Lifelong Learning point in the American Board of Pathology’s Maintenance of Certification (MOC) Program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABPath Continuing Certification (formerly Maintenance of Certification or MOC) credit.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.